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G lobally,  chronic obstructive pulmonary disease (COPD) is a leading cause of disability,  death,  
and the use of healthcare resources [1].  In Japan,  COPD 
was the tenth leading cause of death in 2015,  and the 
number of COPD patients is projected to increase.  
COPD is a multisystem disease associated with a num-
ber of significant comorbid illnesses (including cardio-
vascular disease) that can cause or contribute to moder-
ate COPD exacerbations [2].
There are proven benefits to using β-blockers in the 
treatment of hypertension,  ischemic heart disease,  and 
heart failure.  However,  β-blockers have historically 
been avoided in asthma treatment because of the risk of 
acute bronchospasm [3-5].  These concerns also apply to 
COPD,  with evidence of a reduction in forced expira-
tory volume in one second (FEV1),  increased airway 
hyper-responsiveness,  and inhibition of the bronchodi-
lator response to β-agonists in patients receiving 
non-selective β-blockers or high doses of cardioselec-
tive β-blockers [6 , 7].  Many physicians are thus reluc-
tant to prescribe β-blockers for patients with concurrent 
COPD [8].
Several studies have suggested that β-blockers can be 
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Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality 
rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart 
failure,  the effects of β-blockers on COPD patients without heart failure have not been established.  Based on 
previous reports,  we have launched a multicenter,  prospective,  single-arm phase II study to evaluate the 
preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation,  in Japanese individuals with 
moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of 
medication.  The primary endpoint is the rate of mild-to-severe COPD exacerbation.  The results of this study 
will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.  
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safely used for COPD patients with heart failure [9-13].  
In particular,  cardioselective β-blockers such as ateno-
lol and bisoprolol are thought to be safe in COPD with 
heart failure [9 , 12].  Several research groups proposed 
that the use of β-blockers might help reduce the mortal-
ity rate and improve the rate of exacerbation in COPD 
patients with heart failure [10-13].  However,  most of 
the preceding reports were of retrospective studies,  and 
thus prospective interventional studies are required for 
a more definitive assessment of whether β-blockers are 
associated with the lung function and prognosis in 
COPD.
Moreover,  β-blockers might improve mortality and 
the rate of exacerbation for COPD patients with heart 
failure,  but their benefit for COPD patients without 
heart failure has not been well studied.  In addition,  the 
populations of the preceding reports were comprised of 
Europeans and North Americans,  and few studies have 
investigated Japanese subjects.
Therefore,  using a prospective interventional study,  
we wished to examine the use of β-blockers in the man-
agement of COPD by assessing whether the β-blockers 
improve the prognosis.  With the above-mentioned 
background,  we have launched an open-labeled,  multi-
center phase II study aimed at evaluating the preventive 
effect of bisoprolol in COPD exacerbation.  In this 
study,  bisoprolol is used as a cardioselective β-blocker 
because several reports have shown that bisoprolol can 
be safely administered to COPD patients with heart 
failure,  compared to other β-blockers.  Since some 
recent studies have already shown the adequacy of using 
β-blockers in COPD patients with heart failure,  this 
study evaluated COPD patients who do not have heart 
failure but do have hypertension requiring the use of 
some medications.
Study Design
This study is a prospective,  single-arm,  open-labeled 
phase II trial investigating Japanese patients with Global 
Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage 2-4 COPD,  aimed at determining 
whether bisoprolol has a preventive effect on COPD 
exacerbation.  This is a multicenter trial at 33 institu-
tions affiliated with the Okayama Respiratory Disease 
Study Group.  Fig.  1 provides an overview of the study 
design.
Ethical Consideration
This study is being conducted in accord with the 
Declaration of Helsinki,  and the protocol has been 
approved by the institutional review board of each par-
ticipating hospital (Okayama University Hospital,  No.  
1612-007).  The protocol was registered at the website of 
the University Hospital Medical Information Network,  
Japan (protocol identification no.  UMIN000024712).
Study Endpoints
The primary endpoint is the rate of moderate-to-se-
vere COPD exacerbation during an observation period 
of 2 years.  Exacerbation is defined as an increase in,  or 
a new onset of,  more than one respiratory symptom 
(cough,  sputum,  sputum purulence,  wheezing,  or dys-
pnea) lasting 3 days or more and requiring treatment 
with an antibiotic or a systemic corticosteroid.  Severe 
exacerbation is defined as an exacerbation that requires 
hospitalization [14],  and mild exacerbation is defined 
as exacerbation without the need for hospitalization.
Secondary endpoints include the annual decline rate 
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Fig. 1　 Overview of the study design.  
of post-bronchodilator forced expiratory volume in 1 
second (FEV1), the COPD Assessment Test (CAT) 
result, the modified Medical Research Council (mMRC) 
Dyspnea Scale score,  the patient’s health-related quality 
of life as measured by the total score on the St.  George’s 
Respiratory Questionnaire in its COPD-specific version 
(SGRQ-C) [15],  the brain natriuretic peptide level,  the 
blood pressure control status,  and the occurrence of 
adverse events.
Eligibility Criteria
GOLD stage 2–4 COPD patients with hypertension 
without heart failure will be recruited to this study.  The 
detailed inclusion and exclusion criteria are listed in 
Table 1.  Written informed consent must be obtained 
from all patients before registration.
Treatment Methods
After written informed consent has been obtained,  
eligible patients will receive 1.25 mg bisoprolol once 
daily.  This dosage will then be increased from 1.25 mg/day 
to 2.5 mg/day at monthly intervals,  and up to 5 mg/day 
if tolerated.  The medication will be continued after the 
end of this study unless the patient wishes todiscon-
tinue the medication or the study reveals disadvantages 
to using the medication.  Treatment will be paused 
when (1) the patient has a systolic blood pressure val-
ue < 100 mmHg,  or (2) bradycardia with some symp-
toms,  or (3) a heart rate < 50 bpm.  In the case of (1),  
when the patient’s blood pressure recovers to ≥  
110 mmHg,  and in the cases of (2) and (3),  when their 
symptoms are remitted and the heart rate has recovered 
to ≥ 60 bpm,  treatment will restart with a dose one step 
lower than that previously given.  All respiratory medi-
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Table 1　 Patient eligibility
Inclusion criteria
(1) a diagnosis of chronic obstructive pulmonary disease
(2) a postbronchodilator FEV1 (forced expiratory volume in 1 sec) value of ≤70% of the FVC (forced vital capacity)
(3) a postbronchodilator FEV1 value ≤80% of the predicted value
(4) age ≥40 years
(5) 10 pack-years smoking history
(6) hypertension
(7) adequate organ function
Exclusion criteria
(1) patients with severe (NYHA grade 3 or 4) cardiac failure
(2) left ventricular contractility ≤40%
(3) 2nd/3rd-degree atrioventricular block, sinoatrial block, or sick sinus syndrome
(4) variant angina pectoris
(5) severe peripheral circulatory disturbance
(6) pulmonary hypertension from right cardiac failure
(7) a history of pulmonary resection
(8) malignancy with a disease-free interval <3 years
(9) systolic blood pressure of less than 100 mmHg
(10) cardiac rate <60 bpm on a constant basis




(15) use of supplemental oxygen or with an SpO2 <90% (or PaO2 of <60 Torr)
(16) asthma
(17) active interstitial pneumonia
(18) COPD exacerbation or respiratory infection within 4 weeks before registration
(19) pregnant women
(20) current use of a β-blocker
(21) history of hypersensitivity to bisoprolol
(22) patients considered to be inappropriate for this study by the attending physician
cations and antihypertensive medications except 
β-blockers will be permitted during the trial.
All of the enrolled patients will be followed for 
2 years,  and occurrences of moderate-to-severe COPD 
exacerbation will be recorded.  The safety and tolerabil-
ity assessments include the determination of clinical 
history,  blood pressure,  pulse rate,  oxygen saturation 
(SpO2),  12-lead electrocardiogram,  chest X-ray,  clini-
cal laboratory tests,  pulmonary function test,  and 
adverse event recording.
Statistical Analysis
According to the UPLIFT study,  the estimated rate 
of 2-year moderate exacerbations of GOLD stage 2–4 
COPD (tiotropium group) is 67.1% [16].  The authors of 
a retrospective cohort study in which the effects of 
β-blockers on COPD patients were investigated 
reported that the incidence risk ratio representing the 
impact of β-blockers on the exacerbation rate for total 
exacerbations was 0.75 over an average 2-year observa-
tion period [10].  Expecting an approximate 25% 
reduction in the exacerbation rate through the use of 
β-blockers,  an estimated incidence of the annual exac-
erbation rate of 45% and an upper limited incidence of 
67% would be assumed with an alpha error of 0.05 and 
beta error of 0.2; thus,  30 evaluable patients are 
required [17].  With this in mind,  a total of 35 patients 
are to be recruited to this study,  taking into account a 
percentage of unevaluable patients including those 
dropping out of approx.  10%.  In the present study,  no 
predefined interim analysis will be applied.  About 20 
eligible patients per year are anticipated; therefore,  the 
recruiting period was set from December 20,  2016 to 
December 20,  2018.  Including the 2-year follow-up 
period,  this study will be performed until December 
20,  2021.
The effect of bisoprolol will be evaluated using the 
exacerbation rate and its 95% confidence interval.  The 
result of an upper confidence limit of < 67% will reject 
the null hypothesis.
Discussion
Many physicians are reluctant to use β-blockers for 
their patients with COPD,  although it has been 
reported that β-blocker use might benefit COPD 
patients.  For example,  a large observational study con-
ducted in 1998 of COPD patients after myocardial 
infarction demonstrated that the β-blockers improved 
the survival of these COPD patients similarly to other-
wise healthy patients,  those with heart failure,  and 
older patients [18].  In addition,  some studies have 
suggested that cardioselective β-blockers including 
bisoprolol are safe for use in COPD patients with heart 
failure,  indicating that the use of β-blockers reduced the 
mortality rate and decreased the rate of exacerbation 
[10-13].  However,  most of these reports were of retro-
spective studies of COPD patients with heart failure.  
The present prospective study,  which targets COPD 
patients without heart failure,  thus has great value.
In the reports demonstrating the protective effects of 
β-blockers against COPD mortality and exacerbation,  
several potential underlying mechanisms were consid-
ered.  In one of these reports,  it was proposed that the 
effect of β-blockers might decrease exacerbations aris-
ing from cardiovascular causes [19].  Another group 
speculated that the overexpression of β-receptors by the 
administration of β-blockers can,  in turn,  decrease 
bronchoconstriction [20].  Interestingly,  it has also been 
reported that β-blockers suppress airway inflammation 
and mucus production [21] and reduce resting tachy-
cardia,  an independent predictor of mortality in COPD 
[22].
In light of these considerations,  the cardioselective 
β-blocker bisoprolol is expected to have a protective 
effect against exacerbation in COPD and to be able to 
improve the prognosis of COPD patients.  We hope that 
our multicenter,  prospective,  single-arm phase II study 
of the effects of bisoprolol will answer whether this 
β-blocker could become a new therapeutic strategy for 
COPD.
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